~ Buy the TERLIVAZ (terlipressin acetate) Drug Profile, 2024 PDF Report in the Report Store ~

TERLIVAZ Drug Patent Profile

✉ Email this page to a colleague

When do Terlivaz patents expire, and when can generic versions of Terlivaz launch?

Terlivaz is a drug marketed by Mallinckrodt Ireland and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-five patent family members in seventeen countries.

The generic ingredient in TERLIVAZ is terlipressin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the terlipressin acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Terlivaz

Terlivaz will be eligible for patent challenges on September 14, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 14, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for TERLIVAZ?
What are the global sales for TERLIVAZ?
What is Average Wholesale Price for TERLIVAZ?

Summary for TERLIVAZ

International Patents:	35
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	63
Patent Applications:	3,245
Drug Prices:	Drug price information for TERLIVAZ
What excipients (inactive ingredients) are in TERLIVAZ?	TERLIVAZ excipients list
DailyMed Link:	TERLIVAZ at DailyMed

Drug patent expirations by year for TERLIVAZ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TERLIVAZ

Generic Entry Date for TERLIVAZ^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: TO IMPROVE KIDNEY FUNCTION IN ADULTS WITH HEPATORENAL SYNDROME WITH RAPID REDUCTION IN KIDNEY FUNCTION NDA: 022231 Dosage: POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for TERLIVAZ

Drug Class	Vasopressin Receptor Agonist
Mechanism of Action	Vasopressin Receptor Agonists

US Patents and Regulatory Information for TERLIVAZ

TERLIVAZ is protected by one US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TERLIVAZ is ⤷ Sign Up.

This potential generic entry date is based on TO IMPROVE KIDNEY FUNCTION IN ADULTS WITH HEPATORENAL SYNDROME WITH RAPID REDUCTION IN KIDNEY FUNCTION.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TERLIVAZ

Method of treating patients with hepatorenal syndrome type 1
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD TO IMPROVE KIDNEY FUNCTION IN ADULTS WITH HEPATORENAL SYNDROME WITH RAPID REDUCTION IN KIDNEY FUNCTION

FDA Regulatory Exclusivity protecting TERLIVAZ

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up

TO IMPROVE KIDNEY FUNCTION IN ADULTS WITH HEPATORENAL SYNDROME WITH RAPID REDUCTION IN KIDNEY FUNCTION
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt Ireland	TERLIVAZ	terlipressin acetate	POWDER;INTRAVENOUS	022231-001	Sep 14, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Mallinckrodt Ireland	TERLIVAZ	terlipressin acetate	POWDER;INTRAVENOUS	022231-001	Sep 14, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Mallinckrodt Ireland	TERLIVAZ	terlipressin acetate	POWDER;INTRAVENOUS	022231-001	Sep 14, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for TERLIVAZ

See the table below for patents covering TERLIVAZ around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
China	117425488	治疗患有1型肝肾综合征的患者的方法 (Methods of treating patients with hepatorenal syndrome type 1)	⤷ Sign Up
Slovenia	3209317		⤷ Sign Up
Japan	6673915		⤷ Sign Up
Japan	2024522283	１型肝腎症候群を有する患者を治療する方法	⤷ Sign Up
Japan	2022171795	１型肝腎症候群患者の治療方法	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration